Meeting
2018 ASCO Annual Meeting
Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716).
Authors
Siwen Hu-Lieskovan
UCLA's Jonsson Comprehensive Cancer Center, Los Angeles, CA
Siwen Hu-Lieskovan , James Moon , Danae Campos , Kenneth F. Grossmann , Jeffrey Alan Sosman , Christopher W. Ryan , Michael Wu , Antoni Ribas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02965716
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS9603)
DOI
10.1200/JCO.2018.36.15_suppl.TPS9603
Abstract #
TPS9603
Poster Bd #
426a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non–small cell lung cancer (NSCLC; IMP-MEL).
First Author: Nicholas Coupe
First Author: Cailin Joyce
Poster
2020 ASCO Virtual Scientific Program
Design and rationale of MASTERKEY-115 phase II trial of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in patients with advanced melanoma who progressed on prior anti-programmed cell death-1 (anti-PD-1) therapy.
First Author: Jason Alan Chesney
Poster
2020 ASCO Virtual Scientific Program
Investigating the tumor immune infiltrate for populations that predict immune-related adverse events (irAEs) in patients receiving PD-1 inhibitors.
First Author: Steven Michael Blum